Title:Thymosin α1; Potential Therapeutic Implications of an Immunoregulatory Drug in the Treatment of Lymphocytopenia Associated with COVID-19
VOLUME: 16 ISSUE: 1
Author(s):Milad Shirvaliloo*
Affiliation:Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz
Keywords:Thymosin α1, lymphocytopenia, T cells, COVID-19, SARS-CoV-2, immunoregulatory drug.
Abstract:It is not unbeknownst to us that since the very onset of the COVID-19 outbreak, many
patients from different age groups have suffered greatly, and in a remarkable number of cases, succumbed
to their untimely demise as a result of infection with the novel coronavirus or SARS-CoV-
-2. The elderly are perhaps the most vulnerable community, who stand at the pinnacle of morbidity
and mortality rates due to contracting severe forms of COVID-19. Hopefully, based on the recent
findings and the present evidence, there might be a number of medications that would possibly be
of great prophylactic and therapeutic value to the elderly patients diagnosed with COVID-19. According
to an interventional study, Thymosin α1 is arguably one such medication that has recently
been indicated to be an effective therapeutic agent for inpatient management of lymphocytopenia
and T cell exhaustion caused by COVID-19.
